Insufficient fluconazole levels in pediatric patients with cancer treated for invasive candidiasis
the ONA take:
According to a new study published in the journal Clinical Infectious Diseases, researchers have found that the fluconazole concentration in pediatric patients with cancer and invasive candidiasis is not sufficient for treatment with the currently recommended dosing regimen.
For the study, researchers identified 99 critically ill pediatric patients treated with fluconazole from January 2007 to October 2013. Of the 99 patients, 40% had subtherapeutic fluconazole plasma concentrations. Analyses demonstrated a significant and positive association between fluconazole trough concentration and dose (P < 0.001), weight (P = 0.009) and the serum urea concentration (P = 0.003).
In addition, there was a significant and negative association between fluconazole trough concentration and age (P = 0.004) and cancer as the underlying cause of invasive candidiasis (P = 0.003). In addition, they found that a higher fluconazole trough concentration was linked with a decreased duration to culture conversion (HR = 1.076, 95% CI 1.017 - 1.138, P = 0.011).
The findings suggest that a higher dose of fluconazole is necessary to achieve sufficient drug concentrations for the treatment of invasive candidiasis in critically ill pediatric patients with cancer.
Fluconazole in pediatric patients with cancer and invasive candidiasis is not sufficient for treatment.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|